STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [Form 4] Eli Lilly & Co. Insider Trading Activity

[Form 4] Eli Lilly & Co. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock LLY logo
Lilly Eli & Co

NYSE:LLY

LLY Rankings

#11 Ranked by Market Cap
#1894 Ranked by Dividends

LLY Latest News

Jul 9, 2025
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
Jun 23, 2025
Lilly declares third-quarter 2025 dividend
Jun 22, 2025
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Jun 21, 2025
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Jun 17, 2025
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

LLY Latest SEC Filings

Jul 22, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity
Jul 22, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity
Jul 22, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity
Jul 22, 2025
[Form 4] Eli Lilly & Co. Insider Trading Activity

LLY Stock Data

692.83B
945.64M
0.17%
83.56%
0.81%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS